### 1 Chikungunya virus antepartum transmission and abnormal infant outcomes 2 in Nigeria

#### 2 I 3

- 4 Atiene S. Sagay<sup>1,a</sup>, Szu-Chia Hsieh<sup>2,a</sup>, Yu-Ching Dai<sup>2,a</sup>, Charlotte Ajeong Chang<sup>3</sup>, Jerry
- 5 Ogwuche<sup>4</sup>, Olukemi O. Ige<sup>1</sup>, Makshwar L. Kahansim<sup>1</sup>, Beth Chaplin<sup>3</sup>, Godwin Imade<sup>1</sup>, Michael
- 6 Elujoba<sup>4</sup>, Michael Paul<sup>1</sup>, Donald J. Hamel<sup>3</sup>, Hideki Furuya<sup>5</sup>, Ricardo Khoury<sup>6</sup>, Viviane Sampaio
- 7 Boaventura<sup>6</sup>, Laíse de Moraes<sup>6</sup>, Phyllis J. Kanki<sup>3</sup>, Wei-Kung Wang<sup>2</sup>
- 8
- <sup>9</sup> <sup>1</sup>Jos University Teaching Hospital, University of Jos, Jos, Nigeria;
- <sup>10</sup> <sup>2</sup>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns
- 11 School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA;
- <sup>12</sup> <sup>3</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
- 13 Health, Boston, Massachusetts, USA; <sup>4</sup>Our Lady of Apostles Hospital, Jos, Nigeria
- <sup>5</sup>Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, California,
- 15 USA;
- <sup>6</sup>Instituto Gonçalo Moniz –Oswaldo Cruz Foundation (FIOCRUZ), Bahia, Brazil
- 17
- 18 **Correspondence:** Wei-Kung Wang (wangwk@hawaii.edu) and Phyllis J. Kanki
- 19 (pkanki@hsph.harvard.edu),
- <sup>a</sup> These authors contributed equally.
- 21
- 22 Keywords. chikungunya virus; arbovirus ; pregnancy ; perinatal transmission ; congenital
- 23 abnormality ; Africa ; Nigeria
- 24

## 25 ABSTRACT

- 26 Chikungunya virus (CHIKV) has become a global public health concern since the reemergence
- 27 of the Indian Ocean lineage and expansion of the Asian genotype. CHIKV infection causes acute
- febrile illness, rash, and arthralgia and during pregnancy may affect both mothers and infants.
- 29 The mother-to-child transmission (MTCT) of CHIKV in Africa remains understudied. We
- 30 screened 1006 pregnant women at two clinics in Nigeria between 2019 and 2022 and
- 31 investigated the prevalence and MTCT of CHIKV. Of the 1006, 119 tested positive for CHIKV
- 32 IgM, of which 36 underwent detailed laboratory tests. While none of the IgM reactive samples
- 33 were RT-PCR positive, 14 symptomatic pregnant women were confirmed by CHIKV
- neutralization test. Twelve babies were followed with 8 normal and 4 abnormal outcomes,
- 35 including stillbirth, cleft lip/palate with microcephaly, preterm delivery, polydactyly with sepsis
- and jaundice. CHIKV IgM testing identified 3 antepartum transmissions, further studies will
- 37 determine its impact in antepartum infection.

#### 38 Introduction

Chikungunya virus (CHIKV), a member of the genus Alphavirus of the family Togaviridae, is 39 40 transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Prior to 2005, there were 3 distinct genotypes of CHIKV: the East-Central-South African (ECSA), West African and Asian 41 genotypes in different geographic locations (1-3). The ECSA genotype spread from East Africa 42 to the Indian Ocean and Asia between 2004-2007, known as the Indian Ocean lineage (IOL). In 43 addition, the Asian genotype expanded in late 2013, the so-called the Asian-Western Hemisphere 44 lineage, leading to its spread in the Americas with over 1.3 million suspected cases by April 45 2015 (1-3). It has been reported that autochthonous transmission of CHIKV occurs in 114 46 countries and territories over the tropical and sub-tropical areas of Africa, Asia, Oceania, the 47 Americas, and Europe, where greater than three quarters of the world's population reside (1-3). 48 CHIKV in Africa is maintained in an enzootic cycle involving non-human primates and 49 sylvatic Aedes mosquitoes; sporadic cases or outbreaks tend to be small-scaled and associated 50 51 with spillover from the natural reservoir vectors or environmental conditions such as increased rainfall (4-6). Recently, an increase in larger-scale outbreaks associated with urban areas of 52 53 Africa have been reported (2,7,8).

CHIKV infection causes acute febrile illness, rash and arthralgia and may affect both pregnancy and infant outcomes (*9.10*). During the Reunion Island outbreak in 2005, the prospective study of CHIKV infection in pregnancy described mother-to-child transmission (MTCT) was observed in viremic mothers during the intrapartum period (within 2 days prior to and after delivery) with a transmission rate of 48.7%, leading to neonatal disease with sepsis-like illness, encephalitis, convulsions, and death (*11-13*). The study also described 3 exceptional cases of early fetal deaths (before 22 weeks) out of 678 antepartum CHIKV infections which

were attributed to intrauterine CHIKV infection. As CHIKV spread from Asia to the Americas 61 between 2007-2014, perinatal transmission of CHIKV was reported in India, Colombia, Brazil, 62 63 and Curacao (14-17). Meta-analysis of cohort studies from Asia and Latin America revealed a MTCT rate of 15.5% with symptomatic neonatal disease attributed to intrapartum infection 64 (10,18,19). However, the MTCT of African strains of CHIKV remains poorly understood. 65 In this study, we screened 1006 pregnant women at two antenatal clinics in Jos, north-central 66 Nigeria from April 2019 to January 2022. We investigated the prevalence of CHIKV infection 67 among pregnant women, transmission, and disease outcome in infants. 68

69 Methods

#### 70 Nigeria cohort and human samples

Between April 1, 2019 and January 31, 2022, pregnant women aged  $\geq 18$  years, who attended the 71 antenatal clinics at Jos University Teaching Hospital (JUTH) and Our Lady of Apostles Hospital 72 (OLA) in Jos, north-central Nigeria, and presented with fever ( $\geq 37.5^{\circ}$ C) or other symptoms 73 74 (rash, headache, arthralgia, conjunctivitis, or myalgia) in the past 3 days were recruited with informed consent for screening by the Chembio DPP® ZCD IgM/IgG rapid test (Chembio 75 Diagnostics Inc. Medford, NY). For every four symptomatic women, one asymptomatic woman 76 77 with gestational age (GA) within two weeks of any of the four symptomatic women was also recruited for screening. All ZIKV, DENV or CHIKV rapid test IgM and IgM/IgG reactive 78 79 women were recruited with informed consent for the prospective observational study as 80 described (20). The pregnant women with CHIKV infection (CHIKV IgM+ and/or IgG+) and 81 their infants were the focus of this study. The intrapartum period was defined as within 2 days prior to or after delivery (11); the remaining antepartum period included the first, second and 82 third trimesters as defined by GA <12 wk,  $\geq$ 12 wk to <28 wk, and  $\geq$ 28 wk, respectively. 83

84	To evaluate the performance of the Chembio DPP® ZCD IgM/IgG rapid test, convalescent-
85	phase sera from RT-PCR-confirmed CHIKV cases (n=22) in Brazil served as CHIKV-positive
86	reference samples (21) and CHIKV-negative reference samples (n=27) were from a dengue
87	seroprevalence study in Taiwan (22), a CHIKV non-endemic country; both were confirmed by
88	CHIKV pseudovirus neutralization test (NT). Convalescent-phase serum/plasma samples from
89	RT-PCR-confirmed DENV (n=35) and ZIKV (n=42) cases were also included in the analysis
90	(Table S1) (23).
91	The study of coded serum or plasma samples was approved by the Institutional Review
92	Boards (IRB) of the Harvard Longwood Campus (IRB# 17-0654), University of Jos (IRB#
93	127/XIX/5940), and University of Hawaii at Manoa (IRB# 2021-00044).
94	Isolation of viral RNA and RT-PCR
95	Viral RNA was isolated from sera using the QIAamp viral RNA mini kit (Qiagen) and subjected to
96	cDNA synthesis using the SuperScript <sup>™</sup> III first-strand synthesis kit (Thermo Scientific); an
97	aliquot of cDNA was subjected to nested PCR targeting a conserved region of the NSP2 gene of
98	CHIKV (24). The RT-PCR products were electrophoresed through 2% agarose gel, and bands with
99	the predicted size were purified for sequencing. The primers were CHIKV-F (5'-
100	TCAATATGATGCAGATGAAAGT-3', position 2541-2562), CHIKV-inner R (5'-
101	GTCACAGGCA GTGTACACC -3', position 2616-2634) and CHIKV-outer R (5'-
102	GCAACGABGA CACAATGGC-3', position 2536-2654). The size of the 1st round and 2nd round
103	products were 113 bp and 93 bp, respectively. The PCR protocol will be provided upon request.
104	IgM and IgG enzyme-linked immunosorbent assays (ELISAs) using DENV and ZIKV $% \mathcal{A} = \mathcal{A} = \mathcal{A} = \mathcal{A}$
105	mutated virus like particles (VLP)

106 The plasmids expressing envelope protein fusion loop (FL)-mutated DENV1 VLP (Hawaii

107 strain) and FL- and BC loop (BCL)-mutated ZIKV VLP (PRVABC59 strain), generation of

108 VLP, and IgM and IgG ELISA using DENV FL-VLP or ZIKV FL/BCL VLP have been

109 described previously (25). The sensitivity/specificity of DENV FL-VLP and ZIKV FL/BCL VLP

110 IgG ELISAs was 100/93.3% and 100/83.3%, respectively; and that of DENV FL-VLP and ZIKV

111 FL/BCL VLP IgM ELISAs was 75/95.8% and 90/99.3%, respectively.

#### 112 Microneutralization test

113 Microneutralization test was performed as described previously (26,27). Briefly, flat-bottom 96-

well plates were seeded with Vero cells  $(3x10^4 \text{ cells per well})$  24 h prior to infection. Fourfold

serial dilutions of serum (starting from 1:10 final dilution) were mixed with 50 focus-forming

units of DENV1 (Hawaii strain), DENV2 (NGC strain), DENV3 (CH53489), DENV4 (H241

strain), or ZIKV (PRVABC59 strain) at 37°C for 1 h. The mixtures were added to each well

followed by incubation for 48 h (except 70 h for DENV1), removal of medium, and fixation as

described previously (26,27). After adding a murine monoclonal antibody 4G2 and secondary

120 antibody mixture (IRDye 800CW-conjugated goat anti-mouse IgG at 1:10,000 and DRAQ5

121 fluorescent probe at 1:10,000), the signal (800 nm/700 nm fluorescence) was detected using a Li-

122 Cor Odyssey Classic imaging system (Li-Cor Biosciences, Lincoln, NE) and analyzed using

123 Image Studio software to determine percent neutralization at different concentrations and NT<sub>90</sub>

- 124 as described previously (26,27).
- 125 Cell lines and plasmids

126 Human hepatoma Huh7 cells were obtained from Health Science Research Resources Bank,

127 Japan Health Sciences Foundation (Osaka, Japan). HEK-293T cells were obtained from the

128 American Type Culture Collection (Manassas, VA). Plasmids pNL4-3 R-E-miRFP, which

129 contains the monomeric infrared fluorescent protein (miRFP) gene replacing the Luc gene of an

- 130 *env*-defective HIV-1 reporter construct pNL4-3.Luc.R-E-, has been described previously (28).
- 131 The E3-E2-6K-E1 genes of CHIKV (2955 bp) and Mayaro virus (MAYV) (2952 bp) were PCR
- amplified from cDNA derived from RNA of CHIKV (H20235 strain) and MAYV (TRVL
- 133 strain), respectively, (BEI Resources, Manassas, VA), and cloned into pCB vector (by NotI and
- 134 XhoI sites) to generate plasmids CHIKV and MAYV. All plasmids were confirmed by
- sequencing of the entire E3-E2-6K-E1 gene insert and verified for expression by transfection and
- 136 Western blot analysis (28).

#### 137 Generation of CHIKV and MAYV pseudoviruses

- 138 To generate pseudoviruses, HEK-293T cells were seeded in 10-cm dish one day before
- transfection, co-transfected with pNL4-3 R-E-miRFP (12 µg) and plasmids CHIKV (12 µg) or
- 140 MAYV (4 µg) using lipofectamine 2000 and incubated with DMEM media containing 10% FBS
- 141 (28). The supernatants were collected at 72 h post transfection, followed by low-speed
- 142 centrifugation at 300x g for 10 min, aliquoted and stored at -80°C. To titrate each pseudovirus,
- 143 3-fold serially diluted supernatants were inoculated to Huh7 cells by spin infection (28); miRFP
- signals were quantitated at 72 h post-infection, and the amount of pseudovirus that resulted in
- 145 miRFP signals 10 times higher than the mock-infected wells was used for the NT.

#### 146 CHIKV and MAYV pseudovirus NT

- 147 Huh7 cells ( $2 \times 10^4$  cells/well) were seeded onto 96-well plates one day before infection.
- 148 Pseudovirus (CHIKV or MAYV) was mixed with 4-fold serial dilutions of plasma at 1:1 ratio,
- incubated at 37°C for 1 h, and added to each well for spin infection. At 72 h, the plates were
- scanned by Li-Cor Odyssey imager (28). The % of infection at different plasma dilutions (from
- 151 1:10 to 1:10,240 dilutions) were calculated by the formula (intensity of serum+pseudovirus –

152	intensity of media only)/(intensity of pseudovirus only – intensity of media only) x 100. The %
153	neutralization= $100 - \%$ of infection (28). NT <sub>50</sub> titer was the plasma dilution that reached 50%
154	neutralization using 4-parameter nonlinear regression analysis (GraphPad 6.0, Boston, MA)
155	(Figure 1). NT <sub>50</sub> titer<10 was arbitrarily assigned as 5.
156	Statistical analysis
157	The two-tailed Fisher's exact test (Pearson Chi-square test) and two-tailed Mann-Whitney test
158	were used to compare qualitative and quantitative variables, respectively, between two groups;
159	the two-tailed Wilcoxon signed-rank test paired data (GraphPad 6.0, Boston, MA).
160	Results
161	Detection of CHIKV infection
162	The Chembio DPP <sup>®</sup> ZCD IgM/IgG rapid test was used to detect CHIKV IgM and IgG in
163	consenting pregnant women at the antenatal clinics of JUTH and OLA. To assess the
164	sensitivity/specificity of the CHIKV IgM and IgG assays, we first tested with a panel of
165	convalescent-phase samples from RT-PCR-confirmed CHIKV, DENV and ZIKV cases and
166	CHIKV-negative samples from a dengue seroprevalence study in Taiwan (21-23). The
167	sensitivity/specificity of the CHIKV IgM and IgG assays was 90.9/95.2% and 100/100%,
168	respectively (Table S1).
169	Between April 2019 and January 2022, 787 febrile or otherwise symptomatic and 219
170	asymptomatic women were screened. A third of women (312/1006, 31.0%) were reactive to
171	ZIKV, DENV, CHIKV or some combination. CHIKV IgG was detected in 120/1006, suggesting
172	a seroprevalence of 11.9%, and CHIKV IgM in 119/1006 (11.8%), suggesting acute or recent
173	CHIKV infection. Among symptomatic women, headache was the most common symptom
174	followed by fever and fatigue. Unlike similar studies in the Americas, rash and arthralgia were

- not commonly reported. The prevalence of CHIKV IgM was higher in asymptomatic women
- 176 (41/219, 18.7%) compared to symptomatic women (78/787, 9.9%). CHIKV RT-PCR was

177 performed but none of the CHIKV IgM reactive samples tested positive.

### 178 Confirmation of CHIKV infection by NT

- 179 We further generated CHIKV pseudovirus based on a lentivirus vector with an miRFP
- reporter and developed a CHIKV NT (Figure 1) (28). When testing with a panel of convalescent-
- 181 phase sera from RT-PCR-confirmed CHIKV cases in Brazil, we found high NT<sub>50</sub> titers (289-
- 182 6867) to CHIKV (Figure 1). As a comparison, a MAYV pseudovirus NT was also performed and
- 183 lower NT<sub>50</sub> titers (30-1522) to MAYV were observed; the ratio of CHIKV NT<sub>50</sub> titers to MAYV
- 184 NT<sub>50</sub> titers were higher than 2.5, which was consistent with two recent reports (29, 30).
- 185 We next used the CHIKV NT to examine 36 samples, collected during the first two years of
- the study, from 119 pregnant women with acute or recent CHIKV infection (either IgM+IgG+ or
- 187 IgM+IgG–). Of the 36 samples, we found 18 with detectable neutralizing antibodies to CHIKV
- 188 (16 from the IgM+IgG+ subgroup and 2 from the IgM+IgG- subgroup) (Table 1, Figure 2A).
- 189 This is in agreement with the observation of distinct antibody patterns and the presence of an
- 190 IgM+IgG- period in some individuals following CHIKV infection (31).

#### 191 Infant outcomes of antepartum CHIKV infection

192 Of the 36 pregnant women with CHIKV IgM reactivity (either IgM+IgG+ or IgM+IgG-), 30

193 were symptomatic suggesting acute CHIKV infection. Of the 30 women, 26 babies were

194 followed up and 19 had normal and 7 had abnormal outcomes including three stillbirths, two

- multiple congenital anomalies, one polydactyly with sepsis and jaundice, and one preterm (Table
- 1). In the subset of 14 acute CHIKV infections confirmed by NT, 12 babies were followed with 8
- 197 normal and 4 abnormal outcomes.

The time course of 4 mothers with acute CHIKV infection confirmed by NT (Figures 2B-2E) 198 and their babies with abnormal outcomes was summarized in Figures 3A-3D. Notably, babies 199 with multiple congenital anomalies may have lower odds of survival. Case OL-ZP-0031 was 200 enrolled at 39 wk with CHIKV IgM+/IgG- and NT50 titer of 10 to CHIKV; she gave birth to a 201 baby with multiple congenital anomalies including cleft lip, palate and microcephaly who passed 202 203 away in 2 days (Figure 3A). Additionally, past flavivirus infection was confirmed by NT. Case OL-ZP-0028 was enrolled at 33 wk with CHIKV IgM+/IgG+ and high NT<sub>50</sub> titer (of 6657) to 204 CHIKV; due to ZIKV ELISA IgG+, NT was performed and showed NT<sub>90</sub> titer of 51 to ZIKV 205 and <10 to DENV1-4, suggesting past ZIKV infection (Figure 3D). 206

207 Antepartum transmission of CHIKV

Of the 26 CHIKV infections among symptomatic pregnant women with babies followed, one 208 was detected in the first trimester, 8 second trimester and 17 third trimester (Table 2). We further 209 examined the babies' samples to assess the possibility of antepartum transmission; of the 19 210 211 available samples from babies followed, 3 were CHIKV IgM reactive (all in the third trimester with two normal and one preterm outcomes), suggesting antepartum transmission of CHIKV 212 (Table 1). The time course of 3 pregnant women with antepartum CHIKV infection and 213 214 transmission to their babies were summarized in Figures 3D and 3E-3F. Case OL-ZP-0028 gave birth to a preterm baby at 36 wk; the baby at 6 wk (the first follow-up) showed CHIKV 215 216 IgM+/IgG+ (Figure 3D). Another past flavivirus infection confirmed by NT was noted in case 217 OL-ZP-0020, who was enrolled at 37 wk with CHIKV IgM+/IgG+ and high NT<sub>50</sub> titer to 218 CHIKV; due to ZIKV and DENV ELISAs IgG+, NT to ZIKV and DENV was performed and

showed NT<sub>90</sub> titers of 163 to ZIKV, 39 to DENV2 and <10 to DENV1, 3 and 4, suggesting past

ZIKV and DENV infection. She gave birth to a normal baby at 40 wk; the baby followed up at
day 1 showed CHIKV IgM+/IgG+ (Figure 3E).

#### 222 Discussion

In this study, we examined CHIKV infection during pregnancy in a non-outbreak setting in
 Nigeria and reported antepartum transmission of CHIKV and association of antepartum CHIKV
 infection with abnormal infant outcomes.

Based on previous reports from the 2005 Reunion Island outbreak that MTCT of CHIKV 226 occurred predominantly during the intrapartum period, subsequent studies of CHIKV infection 227 during pregnancy primarily focused on the perinatal period and confirmed the contribution of 228 intrapartum CHIKV infection to the MTCT of CHIKV with IOL and Asian genotypes in Asia and 229 Latin America (14-19). Our finding of CHIKV transmission to 3 infants out of 19 (15.8%) 230 pregnant women with antepartum CHIKV infection was unexpected compared with the Reunion 231 Island study, in which 3 abortions out of 678 (0.4%) antepartum CHIKV infections were 232 233 attributed to in utero CHIKV infection. The higher rates of antepartum CHIKV MTCT might be attributed to pathogenesis of endemic infection and/or CHIKV strain differences. Furthermore, we 234 reported 7 abnormal infant outcomes including three stillbirths, two multiple congenital 235 236 anomalies, one polydactyly with sepsis and jaundice, and one preterm associated with 26 antepartum CHIKV infections (26.9%). The 7 abnormal infant outcomes were a subset of 17 237 238 abnormal infant outcomes associated with arbovirus (ZIKV,DENV, and CHIKV) infection during pregnancy, in which birth registry data were compared (20). Notably, another study of the CHIKV 239 240 outbreak in Colombo, Sri Lanka in 2006-2007 reported transmission of CHIKV to 6 infants (based on newborn IgM positivity) out of 46 (13.0 %) pregnant women with antepartum CHIKV 241 infection and 10 (21.7%) abnormal outcomes including two abortions, one intrauterine death, one 242

preterm, five congenital heart diseases (atrial septal defect, patent ductus arteriosus and persistent 243 foramen ovalis) and one intrauterine growth retardation (32). As the Sri Lanka outbreak was 244 245 likely to be caused by the IOL, the difference between our findings and those from the Reunion Island outbreak could not be explained by different CHIKV genotypes alone. 246 A recent review of 13 CHIKV outbreaks in Africa from 1999 to 2020 revealed that viral 247 lineage was identified in 8 outbreaks; all were associated with ECSA genotype (which the IOL 248 originated from) except one outbreak of West African genotype in Kedougou, Senegal during 249 2009-2010, in which 14 out of 144 acute sera at 5 health care facilities were confirmed by 250 CHIKV RT-PCR and 6 CHIKV IgM+ cases were identified from 1409 sera collected (2,5,6). 251 The timing of sample collection after symptom onset differed between studies and may account 252 for the difference in detection by RT-PCR. 253 After CHIKV infection, individuals develop an IgM response starting from 3 to 8 days post-254 symptom onset, followed by an IgG response at 7 to 14 days (33-35). A recent study reported 5 255 256 distinct antibody patterns (IgM-IgG-/NT-, IgM+IgG-/NT-, IgM+IgG-/NT+, IgM+IgG+/NTand IgM+IgG+/NT+) during acute febrile phase and the presence of NT or IgG antibody was 257 associated with protection against developing chronic arthritis in the future, which was supported 258 259 by two studies of outbreaks in India (2010-3 and 2014-6) (31,36). Although most individuals of the IgM-IgG- and IgM+ IgG- subgroups developed IgG and NT antibodies at the convalescent-260 261 phase, this may explain some IgM+IgG- and NT- samples observed in our study. The proportion of inapparent CHIKV infection has been reported to be 3%-25%, 262 corresponding to a symptomatic to inapparent ratio of 1:0.03 to 1:0.33 (2,37). Recent studies of 263 the outbreak in Nicaragua reported a higher proportion of inapparent infection with a 264 symptomatic to inapparent ratio of 1:0.65 to 1:1.20, which varies between lineages and 265

epidemics (*38,39*). Our findings of a symptomatic to inapparent ratio of 1:2 is unexpected, which
may be related to viral lineage differences and the non-outbreak setting.

268 Conventional plaque-reduction neutralization test (PRNT) for CHIKV requires a biosafety level 3 laboratory and is labor intensive and time-consuming (35). Several NTs based on 269 different CHIKV pseudoviruses, replicon particles or genetically modified infectious clones 270 271 containing luciferase or green fluorescent protein as reporters have been developed (40-44). Compared with live virus PRNT, our CHIKV pseudovirus NT can be performed in a biosafety 272 level 2 laboratory and requires fewer plates (one 96-well plate for 6 samples in duplicates vs. 273 eighteen 6-well plates for PRNT), less time (72 h vs. >4 days for PRNT), and less sample 274 volume (20 µL vs. 100 µL for PRNT in duplicates, starting from serum at 1:10 final dilution). 275 Compared with CHIKV pseudovirues using luciferase reporter, our CHIKV pseudovirus 276 employed miRFP reporter which can be quantified by one step of direct imaging without 277 multiple laborious steps (5 min scan vs. ~60 min for a 96-well plate) (Figure 1). Moreover, the 278 279 same plate can be quantified multiple times for kinetic study without generating numerous replicates. Compared with GFP reporter, miRFP has minimal autofluorescence and can be 280 quantified by either direct imaging or flow cytometry to determine the percentage of positive 281 282 cells. Together, these features suggest our CHIKV pseudovirus with miRFP reporter is a simple, practical, and cost-effective tool for neutralization. 283

There are several limitations to our study. First, the sample size of pregnant women with CHIKV infection (IgM+) analyzed (n=36) was small; future studies involving larger sample size are needed to validate these observations. There was no difference in age, ethnic groups, trimesters, and ratio of symptomatic vs. inapparent infection between the 36 pregnant women analyzed and the 83 pregnant women not analyzed in this study (Pearson Chi-square test), except

289	that the 36 women were enrolled exclusively during the first two years of the study. Therefore,
290	the analysis of this subset was unlikely to affect our results. Second, although the babies'
291	samples after delivery or the first follow-up were assessed to identify antepartum transmission,
292	the possibility of neonate CHIKV infection cannot be completely ruled out. For example, the
293	first available follow-up sample for the baby of case OL-ZP-0015 was at 14 wk (Figure 3F);
294	excluding this case resulted in an antepartum transmission rate of 10.5% (2/19), which was still
295	higher than that (0.4%) reported in the Reunion Island study. Third, NT to rule out O'nyong-
296	nyong virus (ONNV), a closely related alphavirus which caused intermittent yet explosive
297	outbreaks in East Africa, was not performed (35,45). Despite previous report of the
298	unidirectional antigenic relationships between the two viruses, some sera still cannot be
299	distinguished by NT (46-49). Since the ONNV outbreak involving both the East and West Africa
300	in 1959-1962, ONNV has been apparently silent for 35 years until 1996-1997 when another
301	outbreak in East Africa (Uganda and Kenya and Tanzania) took place (45,48-50). In Nigeria,
302	only 3 confirmed-ONNV cases (by virus isolation) were reported in 1966 and 1969, suggesting
303	the possibility of ONNV infection among the participants in Nigeria is remote (45).
304	CHIKV was first described in Africa, yet subsequent to the Reunion Island outbreak the
305	epidemiology and pathogenesis in the continent has been infrequently studied. Our study
306	provides new and convenient diagnostic tools for future study. In addition, we describe
307	significant asymptomatic infection and abnormal pregnancy and infant outcomes associated with
308	antepartum CHIKV infection. Future studies are needed to further characterize the risk of
309	antepartum CHIKV infection to pregnant women and their infants in Africa.
310	

# 311 Supplementary Data

312 Appendix Table 1 and Figure 1.

313

### 314 Acknowledgments

We thank the pregnant women at the JUTH and OLA clinics that participated in this study to

advance our knowledge of arbovirus infection. We also thank the clinical, laboratory and data

317 management teams at JUTH and OLA whose efforts enabled this work. This work was

supported by grants R21AI137840 (Kanki) and R01AI149502-03 (Wang) from the National

Institute of Allergy and Infectious Diseases, 5D43TWO10130 (Sagay) from the Fogarty

320 International Center, NIH, and MedRes-2022-0000 0789 (Wang) from the Hawaii Community

321 Foundation. The funders had no role in study design, data collection and analysis, decision to

322 publish, or preparation of the manuscript.

323

#### 324 About the Author

325 Dr. Atiene Sagay is a Professor of Obstetrics and Gynecology at the University of Jos, Nigeria, his research centers on maternal health. Dr. Szu-Chia Hsieh was a Research Scientist at the 326 Department of Tropical Medicine, Medical Microbiology and Pharmacology at the University of 327 328 Hawaii at Manoa during this study and is currently relocated to the Graduate Institute of 329 Anatomy and Cell Biology, College of Medicine, National Taiwan University; her research 330 focuses on arboviruses. Ms. Yu-Ching Dai was a Research Assistant and currently Graduate student at the Department of Tropical Medicine, Medical Microbiology and Pharmacology at the 331 332 University of Hawaii at Manoa; her research focuses on arboviruses.

#### 333 **References**

- 1. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne
- disease. N Engl J Med. 2015;372:1231-9.
- 2. Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The
- 337 global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to
- inform the development and introduction of vaccines. PLoS Negl Trop Dis.
- 339 2022;16:e0010069.
- 340 3. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and
- Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021;15:e0009055.
- 4. Pezzi L, Reusken CB, Weaver SC, Drexler JF, Busch M, LaBeaud AD, et al. GloPID-R
- report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics.
  Antiviral Res. 2019;166:66-81.
- 5. Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak in
- Kedougou, Southeastern Senegal in 2009-2010. Open Forum Infect Dis. 2017;5:ofx259.
- 6. Althouse BM, Guerbois M, Cummings DAT, Diop OM, Faye O, Faye A, et al. Role of
- monkeys in the sylvatic cycle of chikungunya virus in Senegal. Nat Commun. 2018;9:1046.
- 349 7. Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of
- chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg.
- 351 2007;77:727-31.
- 8. Peyrefitte CN, Bessaud M, Pastorino BA, Gravier P, Plumet S, Merle OL, et al. Circulation
  of Chikungunya virus in Gabon, 2006-2007. J Med Virol. 2008;80:430-3.
- 354 9. Charlier C, Beaudoin MC, Couderc T, Lortholary O, Lecuit M. Arboviruses and pregnancy:
- maternal, fetal, and neonatal effects. Lancet Child Adolesc Health. 2017;1:134-46.

356	10. Contopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child
357	transmission of chikungunya virus: A systematic review and meta-analysis. PLoS Negl Trop
358	Dis. 2018;12:e0006510.
359	11. Gérardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al.

360 Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the

island of La Réunion. PLoS Med. 2008;5:e60.

- 12. Fritel X, Rollot O, Gerardin P, Gauzere BA, Bideault J, Lagarde L, et al. Chikungunya
- virus infection during pregnancy, Reunion, France, 2006. Emerg Infect Dis. 2010;16:418-25.
- 13. Ramful D, Sampériz S, Fritel X, Michault A, Jaffar-Bandjee MC, Rollot O, et al. Antibody
- 365 kinetics in infants exposed to chikungunya virus infection during pregnancy reveals absence
- of congenital infection. J Infect Dis. 2014;209:1726-30.
- 14. Kumar S, Agrawal G, Wazir S, Kumar A, Dubey S, Balde M, et al. Experience of perinatal
- 368 and neonatal chikungunya virus (Chikv) infection in a tertiary care neonatal centre during

outbreak in North India in 2016: a case series. J Trop Pediatr. 2019;65:169-75.

- 370 15. Villamil-Gomez W, Alba-Silvera L, Menco-Ramos A, Gonzalez-Vergara A, Molinares-
- 371 Palacios T, Barrios-Corrales M, et al. Congenital chikungunya virus infection in Sincelejo,
- Colombia: a case series. J Trop Pediatr. 2015;61:386-92.
- 16. Bandeira AC, Campos GS, Sardi SI, Rocha VF, Rocha GC. Neonatal encephalitis due to
- chikungunya vertical transmission: first report in Brazil. ID Cases. 2016;5:57-9.
- 17. van Enter BJD, Huibers MHW, van Rooij L, Steingrover R, van Hensbroek MB, Voigt RR,
- et al. Perinatal outcomes in vertically infected neonates during a chikungunya outbreak on the
- Island of Curacao. Am J Trop Med Hyg. 2018;99:1415-8.

378	18. Torres JR, Falleiros-Arlant LH, Dueñas L, Pleitez-Navarrete J, Salgado DM, Castillo JB.
379	Congenital and perinatal complications of chikungunya fever: a Latin American experience.
380	Int J Infect Dis. 2016;51:85-88.
381	19. Escobar M, Nieto AJ, Loaiza-Osorio S, Barona JS, Rosso F. Pregnant women hospitalized
382	with chikungunya virus infection, Colombia, 2015. Emerg Infect Dis. 2017;23:1777-83.
383	20. Ogwuche J, Chang CA, Ige O, Sagay AS, Chaplin B, Kahansim ML, et al. Arbovirus
384	surveillance in pregnant women in north-central Nigeria, 2019-2022. submitted. 2023.
385	21. de Moraes L, Cerqueira-Silva T, Nobrega V, Akrami K, Santos LA, Orge C, et al. A
386	clinical scoring system to predict long-term arthralgia in chikungunya disease: A cohort
387	study. PLoS Negl Trop Dis. 2020;14(7):e0008467.
388	22. Tsai JJ, Liu CK, Tsai WY, Liu LT, Tyson J, Tsai CY, et al. Seroprevalence of dengue in
389	two districts of Kaohsiung city after the largest dengue outbreak in Taiwan since world war
390	II. PLoS Negl Trop Dis 2018;12:e0006879.
391	23. Tyson J, Tsai WY, Tsai JJ, Brites C, Mässgård L, Youn HH, et al. Combination of non-
392	structural protein 1-based enzyme-linked immunosorbent assays can detect and distinguish
393	various dengue virus and Zika virus infections. J Clin Microbiol. 2019;57: e01464-18.
394	24. Waggoner JJ, Ballesteros G, Gresh L, Mohamed-Hadley A, Tellez Y, Sahoo MK, et al.
395	Clinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and chikungunya
396	virus detection. J Clin Virol. 2016;78:57-61.
397	25. Tsai WY, Driesse K, Tsai JJ, Granat RS, Jenkins O, Hsieh SC, et al. Enzyme-linked
398	immunosorbent assays using virus-like particles containing mutations of conserved residues
399	on envelop protein can distinguish three flavivirus infections. Emerg Microbe Infect
400	2020;9:1722-32.

401	26. Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, et al.
402	Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus
403	particles: implication for novel strategy of dengue vaccine. J Virol. 2018;92:e00556-18.
404	27. Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, et al. T cell responses to
405	nonstructural protein 3 distinguish infections by dengue and Zika viruses. mBio 2018;9:
406	e00755-18.
407	28. Tsai WY, Ching LC, Hsieh SC, Melish ME, Nerriah VR, Wang WK. A real-time and high-
408	throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric
409	infrared fluorescent protein as reporter. Emerg Microbe Infect. 2021;10:894-905.
410	29. Martins KA, Gregory MK, Valdez SM, Sprague TR, Encinales L, Pacheco N, et al.
411	Neutralizing antibodies from convalescent chikungunya virus patients can cross-
412	neutralize Mayaro and Una viruses. Am J Trop Med Hyg. 2019;100:1541-44.
413	30. Bopp NE, Jencks KJ, Siles C, Guevara C, Vilcarromero S, Fernández D, et al. Serological
414	responses in patients infected with Mayaro virus and evaluation of cross-protective responses
415	against chikungunya virus. Am J Trop Med Hyg. 2021;106:607-9.
416	31. Nayak K, Jain V, Kaur M, Khan N, Gottimukkala K, Aggarwal C, et al. Antibody response
417	patterns in chikungunya febrile phase predict protection versus progression to chronic
418	arthritis. JCI Insight. 2020;5:e130509.
419	32. Senanayake MP, Senanayake SM, Vidanage KK, Gunasena S, Lamabadusuriya SP.
420	Vertical transmission in chikungunya infection. Ceylon Med J. 2009;54:47-50.
421	33. Chua CL, Sam IC, Chiam CW, Chan YF. The neutralizing role of IgM during
422	early chikungunya virus infection. PLoS One. 2017;12:e0171989.

- 423 34. Patil HP, Gosavi M, Kulkarni R, Mishra AC, Arankalle VA. Immunoglobulin G subclass
  424 response after chikungunya virus infection. Viral Immunol. 2022;35:437-42.
- 425 35. Griffin DE. 2013. Chapter 23 Alphaviruses. Knipe DM, Howley PM, eds. Fields virology,
- 426 6th ed, Philadelphia: Lippincott William & Wilkins. pp 651-686.
- 427 36. Jain J, Nayak K, Tanwar N, Gaind R, Gupta B, Shastri JS, et al. Clinical, serological, and
- virological analysis of 572 chikungunya patients from 2010 to 2013 in India. Clin Infect Dis.
  2017;65:133-40.
- 430 37. Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a
- 431 re-emerging infectious disease. Clin Infect Dis. 2009;49:942-8.
- 432 38. Bustos Carrillo F, Collado D, Sanchez N, Ojeda S, Lopez Mercado B, Burger-Calderon R,
- 433 et al. Epidemiological evidence for lineage-specific differences in the risk of
- 434 inapparent chikungunya virus infection. J Virol. 2019;93:e01622-18.
- 435 39. Gordon A, Gresh L, Ojeda S, Chowell G, Gonzalez K, Sanchez N, et al. Differences in
- 436 transmission and disease severity between 2 successive waves of chikungunya. Clin Infect
- 437 Dis. 2018;67:1760-7.
- 438 40. Kishishita N, Takeda N, Anuegoonpipat A, Anantapreecha S. Development of a
- 439 pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection. J
- 440 Clin Microbiol. 2013;51:1389-95.
- 441 41. Henss L, Yue C, Kandler J, Faddy HM, Simmons G, Panning M, et al. Establishment of an
- 442 alphavirus-specific neutralization assay to distinguish infections with different members of
- the Semliki Forest complex. Viruses. 2019;11:82.
- 444 42. Su C, Ding K, Xu J, Wu J, Liu J, Shen J, et al. Preparation and application of
- chi pseudovirus containing double reporter genes. Sci Rep. 2022;12:9844.

446	43. Deng CL, Liu SQ, Zhou DG, Xu LL, Li XD, Zhang PT, et al. Development
447	of neutralization assay using an eGFP chikungunya virus. Viruses. 2016;8:181.
448	44. Schmidt C, Perkovic M, Schnierle BS. Development of a sensitive detection method for
449	alphaviruses and its use as a virus neutralization assay. Viruses. 2021;13:1191.
450	45. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al. GloPID-R
451	chikungunya, o'nyong-nyong and Mayaro virus Working Group. GloPID-R report
452	on chikungunya, o'nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of
453	o'nyong-nyong virus. Antiviral Res. 2019;172:104611.
454	46. Chanas AC, Hubalek Z, Johnson BK, Simpson DI. A comparative study of O'nyong nyong
455	virus with chikungunya virus and plaque variants. Arch Virol. 1979;59:231-8.
456	47. Henss L, Yue C, Von Rhein C, Tschismarov R, Lewis-Ximenez LL, Dölle A, et al.
457	Analysis of humoral immune responses in chikungunya virus (CHIKV)-infected patients and
458	individuals vaccinated with a candidate CHIKV vaccine. J Infect Dis. 2020;221:1713-23.
459	48. Clements TL, Rossi CA, Irish AK, Kibuuka H, Eller LA, Robb ML, et al. Chikungunya and
460	O'nyong-nyong viruses in Uganda: implications for diagnostics. Open Forum Infect Dis.
461	2019;6:ofz001.
462	49. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al. High rates
463	of o'nyong nyong and chikungunya virus transmission in coastal Kenya. PLoS Negl Trop
464	Dis. 2015;9:e0003436.
465	50. Shah MM, Ndenga BA, Mutuku FM, Okuta V, Ronga CO, Chebii PK, et al. No Evidence
466	of O'nyong-nyong viremia among children with febrile illness in Kenya (2015-2018). Am J
467	Trop Med Hyg. 2021;104:1435-7.
468	

CHIKV	Dragnant	Symptomatic	Infants	Infant outcomes			
Serological tests*	women n=36	pregnant women n=30	follow-up n=26	normal n=19	abnormal n=7		
IgM+IgG-	17	15					
NT+	2	2	2	0	1 multiple congenital anomalies (cleft lip/ palate/microcephaly) 1 polydactyly/sepsis/jaundice		
NT-	15	13	11	8	<ol> <li>stillbirth</li> <li>stillbirth and preterm</li> <li>multiple congenital anomalies (hypotonia/ seizure/microcephaly)</li> </ol>		
IgM+IgG+	19	15					
NT+	16	12	10	8 (2 antepartum transmission)	1 stillbirth 1 preterm (antepartum transmission)		
NT-	3	3	3	3	0		

#### 471 Table 1. Serological evidence of CHIKV infection during pregnancy and infant outcomes

\* Chembio DPP® ZCD IgM/IgG rapid test was performed to detect CHIKV IgM and IgG, followed by

CHIKV pseudovirus neutralization test (NT).

Table 2. Time of CHIKV infection during pregnancy and infant outcomes

		Symptomatic		CHIKV infection during pregnancy			
CHIKV Serological tests*	Pregnant women n=36	pregnant women n=30	Infants follow-up n=26	1 <sup>st</sup> trimester n=1	2 <sup>nd</sup> trimester n=8	3 <sup>rd</sup> trimester prior to labor n=17	intrapartum n=0
IgM+ IgG-	17	15					
NT+	2	2	2	0	1 (†)	1 (¶)	0
NT-	15	13	11	1	4	6 (\$‡\$)	0
IgM+ IgG+	19	15					
NT+	16	12	10	0	1	9 (‡#)	0
NT-	3	3	3	0	2	1	0

\* Chembio DPP® ZCD IgM/IgG rapid test was performed to detect CHIKV IgM and IgG, followed by

CHIKV pseudovirus neutralization test (NT).

Infants with abnormal outcomes are shown in parenthesis:

† polydactyly/sepsis/jaundice.

¶ multiple congenital anomalies (cleft lip/palate/microcephaly).

\$ multiple congenital anomalies (hypotonia/seizure/microcephaly).

‡ stillbirth.

s stillbirth and preterm. The time course of 3 pregnant women with acute CHIKV infection not confirmed by NT and their infants with abnormal outcomes

was summarized in Appendix Figure 1.

486 487 488 489 # preterm.



- 490
- 491
- 492

493 **Figure 1.** Generation of CHIKV and MAYV pseudoviruses and NT.

- (A) Schematic drawing of plasmids expressing E2 and E1 proteins (E3-E2-6K-E1 genes) of
- 495 CHIKV or MAYV and co-transfection with pNL43 R-E-miRFP (miRFP) to generate CHIKV or
- 496 MAYV pseudoviruses containing miRFP reporter, infection of target cells and one-step
- 497 imagining. (B) NTs based on CHIKV and MAYV pseudoviruses with miRFP reporter. The
- 498 miRFP signals (left) and neutralization curves and NT<sub>50</sub> titers (right) to CHIKV and MAYV
- 499 pseudoviruses at 72 h post-infection in Huh7 cells of convalescent-phase serum sample from an
- 500 RT-PCT-confirmed CHIKV case from Brazil. (C) Neutralization curves and NT<sub>50</sub> titers to
- 501 CHIKV and MAYV pseudoviruses of other 2 confirmed CHIKV cases. (D) NT<sub>50</sub> titers to
- 502 CHIKV and MAYV pseudoviruses of 22 confirmed CHIKV cases and 27 CHIKV-negative
- individuals. The two-tailed Mann-Whitney (left) and Wilcoxon signed-rank (right) tests
- 504 (GraphPad 6.0).
- 505



**Figure 2.** CHIKV pseudoviruses NT in Nigeria pregnant women. (A) CHIKV NT<sub>50</sub> titers in different subgroups based on CHIKV IgM/IgG results using Chembio DPP<sup>®</sup> ZCD IgM/IgG rapid test. (B-E) Neutralization curves and NT<sub>50</sub> titers to CHIKV and MAYV pseudoviruses of 4 pregnant women with acute CHIKV infection and abnormal infant outcomes. Data are means and standard deviations of duplicates from one experiment.

513



- Figure 3. Time course of pregnant women who had acute CHIKV infection confirmed by NT
  and gave birth to babies with abnormal outcomes or antepartum transmission. (A-D) Time course
  of 4 pregnant women with acute CHIKV infection and abnormal infant outcomes. Multiple
  congenital anomalies with cleft lip/palate and microcephaly (A), stillbirths (B),
  polydactyly/sepsis/ jaundice (C), and preterm (D). (D, E-F) Time course of 3 pregnant women
  with acute CHIKV infection and antepartum transmission of CHIKV to fetus. GA, gestational
  age; wk, weeks; Z, Zika virus; D, dengue virus; C, chikungunya virus. CHIKV IgM-reactive
- 524 infants highlighted in red.